With JUVÉDERM® VOLUX™ XC, You Can
Receive Non-Surgical Jawline Augmentation in Your Aesthetic
Provider's Office
IRVINE,
Calif., Jan. 18, 2023 /PRNewswire/ -- Today,
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced
the highly anticipated national launch of
JUVÉDERM® VOLUX™ XC. The long-lasting hyaluronic
acid (HA) filler is now available at aesthetic practices for
consumers over the age of 21 with moderate to severe loss of
jawline definition.1
"With 40% of aesthetically-aware consumers considering treatment
in the next year to their jawline or jowls with dermal
filler,2* Allergan Aesthetics is excited to address this
need by offering JUVÉDERM® VOLUX™ XC, a specifically
designed and well-researched solution," said Carrie Strom, President, Global Allergan
Aesthetics and Senior Vice President, AbbVie. "As the
category leader, we continue to innovate by providing aesthetic
specialists and patients the broadest portfolio of differentiated
fillers."1,3-7
"Many different types of patients can benefit from
JUVÉDERM® VOLUX™ XC whether you want to address the
appearance of jowls or the contour of the jawline," said Dr.
Sachin Shridharani, board-certified
plastic surgeon.1 "With the addition of this new dermal
filler to the JUVÉDERM® Collection, I can create a
smooth, natural-looking, and long-lasting contour that lasts up to
twelve months with optimal treatment."1
JUVÉDERM® VOLUX™ XC is the newest member of the
JUVÉDERM® Collection, and offers a minimally invasive,
non-surgical treatment option with minimal downtime.1 In
the JUVÉDERM® VOLUX™ XC clinical trial, patients
reported high satisfaction with the results of their
treatment.1 The JUVÉDERM® Collection is the
number one chosen dermal filler collection in the
U.S.8† Additionally, in a survey of
aesthetic providers with experience using three or
more dermal filler brands, the JUVÉDERM® brand
was preferred over two times more than other dermal filler
brands.9‡
"The shape of the jawline has a profound effect on an
individual's appearance,10 which makes treating this
area challenging and requires the practitioner to have advanced
skills and precision," said Dr. David
Shafer, double board-certified plastic surgeon and Allergan
Medical Institute (AMI) trainer. "With the approval of
JUVÉDERM® VOLUX™ XC, the AMI curriculum has expanded to
include in-depth training, robust clinical trial data, and
resources backed by science to ensure that providers have the
proper knowledge and technique required to safely treat appropriate
patients to meet their aesthetic goals."
Commonly reported side effects in the clinical study included
tenderness, lumps/bumps, pain, swelling, firmness, bruising,
redness, itching, and discoloration at the injection sites, as
reported in their 30-day daily diaries.1 These side
effects are consistent with HA filler injections and were usually
mild (causing little discomfort and no effect on daily activities)
or moderate (causing some discomfort and effect on daily
activities) in severity.1 Most of these side effects
went away on their own within two weeks.1
Consumers and new patients who receive aesthetic treatment from
the JUVÉDERM® Collection of Fillers, can also enroll in
Allē, the Allergan Aesthetics loyalty rewards program to unlock
access to curated content, exclusive offers, and personalized
rewards that can be used for savings on the Allergan Aesthetics
portfolio of products and redeemed at a participating provider's
office, subject to applicable program terms and conditions. Allē is
the first and only loyalty program in the aesthetics market to also
offer consumers the ability to earn points on over 40 non-Allergan
Aesthetics treatments and brands.
For more information on the JUVÉDERM® Collection of
Fillers, visit Juvederm.com and follow @JUVEDERM on Instagram.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture,
and market a portfolio of leading aesthetics brands and products.
Our aesthetics portfolio includes facial injectables, body
contouring, plastics, skin care, and more. Our goal is to
consistently provide our customers with innovation, education,
exceptional service, and a commitment to excellence, all with a
personal touch. For more information,
visit www.AllerganAesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas: immunology,
oncology, neuroscience, eye care, virology, women's health and
gastroenterology, in addition to products and services across its
Allergan Aesthetics portfolio. For more information about AbbVie,
please visit us at www.abbvie.com.
Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
JUVÉDERM® Injectable Gel Fillers Important
Information
APPROVED USES
JUVÉDERM® VOLUX™ XC injectable gel is for deep
injection to improve moderate to severe loss of jawline definition
in adults over the age of 21.
JUVÉDERM® VOLUMA® XC injectable gel is for
deep injection in the cheek area to correct age-related volume loss
and for augmentation of the chin region to improve the chin profile
in adults over 21.
JUVÉDERM® VOLLURE® XC,
JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra
XC injectable gels are for injection into the facial tissue for the
correction of moderate to severe facial wrinkles and folds, such as
nasolabial folds. JUVÉDERM® VOLLURE® XC
injectable gel is for adults over 21.
JUVÉDERM® Ultra XC injectable gel is also for
injection into the lips and perioral area for lip augmentation in
adults over 21.
JUVÉDERM® VOLBELLA® XC injectable gel is for
injection into the lips for lip augmentation and correction of
perioral lines, and for injection into the undereye hollows to
improve the appearance of undereye hollows in adults over the age
of 21.
IMPORTANT SAFETY INFORMATION
Are there any reasons why I should not receive any
JUVÉDERM® formulation?
Do not use these products if you have a history of multiple
severe allergies or severe allergic reactions (anaphylaxis), if you
are allergic to lidocaine or the Gram-positive bacterial proteins
used in these products, or if you have had previous allergic
reactions to hyaluronic acid fillers.
What warnings should my doctor advise me about?
- One of the risks with using dermal fillers is the unintentional
injection into a blood vessel. The chances of this happening are
very small, but if it does happen, the complications can be serious
and may be permanent. These complications, which have been reported
for facial injections, can include vision abnormalities, blindness,
stroke, temporary scabs, or permanent scarring of the skin. Most of
these events are irreversible.
- If you have changes in your vision, signs of a stroke
(including sudden difficulty speaking, numbness or weakness in your
face, arms or legs, difficulty walking, face drooping, severe
headache, dizziness, or confusion), white appearance of the skin,
or unusual pain during or shortly after treatment, you should
notify your health care practitioner immediately.
- The use of dermal fillers where skin sores, pimples, rashes,
hives, cysts, or infections are present should be postponed, as
this may delay healing or make skin problems worse.
- The effectiveness of removal of any dermal filler has not been
studied.
What precautions should my doctor advise me about?
- JUVÉDERM® VOLBELLA® XC should only be
injected into undereye hollows by doctors who have completed the
necessary training for this treatment area. To find a doctor, visit
Juvederm.com/find-a-specialist. Doctors who complete the training
will be listed with a symbol.
- The safety of these products for use during pregnancy or while
breastfeeding has not been studied.
- The safety of JUVÉDERM® VOLUMA® XC has
not been studied in patients under 35 years or over 65 years for
cheek augmentation, or under 22 years and over 80 years for chin
augmentation. The safety of JUVÉDERM® VOLUX™ XC,
JUVÉDERM® VOLLURE® XC and
JUVÉDERM® VOLBELLA® XC has not been studied
in patients under 22 years, and the safety of JUVÉDERM®
Ultra Plus XC and JUVÉDERM® Ultra XC has not been
studied in patients under 18 years.
- The safety and effectiveness of treatment with
JUVÉDERM® products in anatomical regions outside of
their approved uses have not been established in clinical
studies.
- If you have a history of excessive scarring (thick, hard scars)
or pigmentation disorders, treatment in these patients has not been
studied and may result in additional scars or changes in
pigmentation.
- If you are planning other procedures including laser treatments
or a chemical peel, there is a possible risk of inflammation at the
treatment site if these procedures are performed closely before or
after JUVÉDERM® injectable gel treatment.
- Tell your doctor if you are on therapy used to reduce your
body's natural defense system (such as steroids, chemotherapy, and
medicines to treat autoimmune diseases, HIV, and AIDs), as these
may increase your risk of infection; and medications that can
prolong bleeding (such as aspirin, ibuprofen, or other blood
thinners), as these may result in increased bruising or bleeding at
the injection site.
- Avoid applying makeup for 12 hours after treatment and minimize
strenuous exercise, exposure to extensive sun or heat, and
alcoholic beverages within the first 24 hours following treatment,
as these may cause temporary redness, swelling, and/or itching at
the injection site.
- JUVÉDERM® VOLUMA® XC was not studied in
patients with significant loose skin of the chin, neck, or
jaw.
- The effect of JUVÉDERM® VOLUMA® XC
injection into the chin on facial hair growth has not been
studied.
- Patients who experience skin injury near the site of
JUVÉDERM® VOLUMA® XC injection may be at a
higher risk for adverse events.
- Tell your doctor if you have already been injected with dermal
fillers in the same area as the one(s) you are about to be treated
for. This information helps your doctor decide when and whether you
should get treatment.
What are possible side effects of treatment?
The most commonly reported side effects with
JUVÉDERM® injectable gels were redness, swelling, pain,
tenderness, firmness, lumps/bumps, bruising, discoloration, and
itching. For JUVÉDERM® VOLBELLA® XC, dryness
was also reported.
These side effects are consistent with other facial injection
procedures and most will resolve within 30 days. Your doctor may
choose to treat side effects persisting longer with antibiotics,
steroids, or hyaluronidase (an enzyme that breaks down hyaluronic
acid).
As with all skin injection procedures, there is a risk of
infection.
To report a side effect with any product in the
JUVÉDERM® Collection, please call the
Allergan® Product Support Department at
1-877-345-5372. Please also visit Juvederm.com or talk to your
doctor for more information.
Products in the JUVÉDERM® Collection are available
only by a licensed physician or properly licensed practitioner.
* ASAPS Practice Survey Data, 2019 (N =
331)2
† Based on 2022 Market Research
Data3
‡ Based on a quantitative survey fielded in
May-June 2022 (n=354). Participants
were current injectors of JUVÉDERM® fillers and must
have used at least two other aesthetic dermal fillers from two
separate aesthetics companies
References
- JUVÉDERM® VOLUX™ XC Patient Label 2022
- Data on File, Allergan, VOLUX Consumer Topline Results,
February 4, 2022
- JUVÉDERM® VOLUMA® XC Patient
Label 2020
- JUVÉDERM® VOLBELLA® XC Patient
Label 2020
- JUVÉDERM® VOLLURE® XC Patient
Label 2020
- JUVÉDERM® Ultra Plus XC Patient Label 2020
- JUVÉDERM® Ultra XC Patient Label 2020
- Data on File, Allergan, Dermal Filler AMT, August 2022
- Data on File, Allergan, AGN Corporate Image Report,
July 2022
- Braz A, Cazerta de Paula Eduardo
C. Reshaping the lower face using injectable fillers. Indian
J Plast Surg. 2020;53:207-218
View original content to download
multimedia:https://www.prnewswire.com/news-releases/juvederm-volux-xc-for-improvement-of-jawline-definition-now-available-nationwide-301724213.html
SOURCE AbbVie